NM_000782.5:c.1226T>C

Variant summary

Our verdict is Uncertain significance. The variant received 3 ACMG points: 8P and 5B. PP5_Very_StrongBS1_SupportingBS2

The NM_000782.5(CYP24A1):​c.1226T>C​(p.Leu409Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00174 in 1,613,914 control chromosomes in the GnomAD database, including 4 homozygotes. Variant has been reported in ClinVar as Likely pathogenic (★★).

Frequency

Genomes: 𝑓 0.00079 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0018 ( 4 hom. )

Consequence

CYP24A1
NM_000782.5 missense

Scores

5
13
1

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:13

Conservation

PhyloP100: 8.62

Publications

43 publications found
Variant links:
Genes affected
CYP24A1 (HGNC:2602): (cytochrome P450 family 24 subfamily A member 1) This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This mitochondrial protein initiates the degradation of 1,25-dihydroxyvitamin D3, the physiologically active form of vitamin D3, by hydroxylation of the side chain. In regulating the level of vitamin D3, this enzyme plays a role in calcium homeostasis and the vitamin D endocrine system. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
CYP24A1 Gene-Disease associations (from GenCC):
  • hypercalcemia, infantile, 1
    Inheritance: AR Classification: STRONG, LIMITED Submitted by: G2P, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae)
  • autosomal recessive infantile hypercalcemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Uncertain_significance. The variant received 3 ACMG points.

PP5
Variant 20-54158096-A-G is Pathogenic according to our data. Variant chr20-54158096-A-G is described in ClinVar as Pathogenic/Likely_pathogenic. ClinVar VariationId is 29680.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population nfe. GnomAdExome4 allele frequency = 0.00184 (2696/1461544) while in subpopulation NFE AF = 0.00231 (2571/1111976). AF 95% confidence interval is 0.00224. There are 4 homozygotes in GnomAdExome4. There are 1297 alleles in the male GnomAdExome4 subpopulation. Median coverage is 32. This position passed quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Homozygotes in GnomAdExome4 at 4 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CYP24A1NM_000782.5 linkc.1226T>C p.Leu409Ser missense_variant Exon 9 of 12 ENST00000216862.8 NP_000773.2 Q07973-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CYP24A1ENST00000216862.8 linkc.1226T>C p.Leu409Ser missense_variant Exon 9 of 12 1 NM_000782.5 ENSP00000216862.3 Q07973-1

Frequencies

GnomAD3 genomes
AF:
0.000788
AC:
120
AN:
152252
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.000362
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000327
Gnomad ASJ
AF:
0.000576
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00143
Gnomad OTH
AF:
0.000478
GnomAD2 exomes
AF:
0.000749
AC:
188
AN:
251066
AF XY:
0.000781
show subpopulations
Gnomad AFR exome
AF:
0.000308
Gnomad AMR exome
AF:
0.000549
Gnomad ASJ exome
AF:
0.000695
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00135
Gnomad OTH exome
AF:
0.000490
GnomAD4 exome
AF:
0.00184
AC:
2696
AN:
1461544
Hom.:
4
Cov.:
32
AF XY:
0.00178
AC XY:
1297
AN XY:
727076
show subpopulations
African (AFR)
AF:
0.000358
AC:
12
AN:
33478
American (AMR)
AF:
0.000514
AC:
23
AN:
44722
Ashkenazi Jewish (ASJ)
AF:
0.000536
AC:
14
AN:
26130
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39690
South Asian (SAS)
AF:
0.0000812
AC:
7
AN:
86256
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53130
Middle Eastern (MID)
AF:
0.000347
AC:
2
AN:
5768
European-Non Finnish (NFE)
AF:
0.00231
AC:
2571
AN:
1111976
Other (OTH)
AF:
0.00111
AC:
67
AN:
60394
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.438
Heterozygous variant carriers
0
182
364
546
728
910
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
112
224
336
448
560
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000788
AC:
120
AN:
152370
Hom.:
0
Cov.:
33
AF XY:
0.000725
AC XY:
54
AN XY:
74514
show subpopulations
African (AFR)
AF:
0.000361
AC:
15
AN:
41600
American (AMR)
AF:
0.000327
AC:
5
AN:
15310
Ashkenazi Jewish (ASJ)
AF:
0.000576
AC:
2
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5190
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4826
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10626
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00143
AC:
97
AN:
68026
Other (OTH)
AF:
0.000473
AC:
1
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.510
Heterozygous variant carriers
0
9
17
26
34
43
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00119
Hom.:
4
Bravo
AF:
0.000858
TwinsUK
AF:
0.000809
AC:
3
ALSPAC
AF:
0.00285
AC:
11
ESP6500AA
AF:
0.000681
AC:
3
ESP6500EA
AF:
0.00163
AC:
14
ExAC
AF:
0.000708
AC:
86
EpiCase
AF:
0.00185
EpiControl
AF:
0.00142

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hypercalcemia, infantile, 1 Pathogenic:9
Jul 08, 2019
Knight Diagnostic Laboratories, Oregon Health and Sciences University
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jun 25, 2024
Fulgent Genetics, Fulgent Genetics
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 20, 2023
Duke University Health System Sequencing Clinic, Duke University Health System
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:research

- -

Sep 05, 2024
Illumina Laboratory Services, Illumina
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

May 01, 2025
Rare Kidney Stone Consortium and the Mayo Clinic Hyperoxaluria Center, Mayo Clinic
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:research

ACMG: PS1, PS3, PM3,PP3, PP4 -

Nov 25, 2022
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: CYP24A1 c.1226T>C (p.Leu409Ser) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00075 in 251066 control chromosomes. This frequency does not allow conclusions about variant significance. c.1226T>C has been reported in the literature in multiple individuals affected with features of Hypercalcemia, Infantile type 1, Hypercalciuric Nephrolithiasis and Nephrocalcinosis, including one case of apparent homozygosity due to UPD(20)mat leading to infantile hypercalcemia (example, Schlingmann_2011, Dinour_2013, Mugg_2015, Hureaux_2021). These data indicate that the variant is very likely to be associated with disease. At least two publications report experimental evidence evaluating an impact on protein function (example, Schlingmann_2011 and Mugg_2015). The most pronounced variant effect results in <10-30% of normal CYP24A1 enzyme activity. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (Pathogenic/Likely pathogenic, n=5; VUS, n=1). Based on the evidence outlined above, the variant was classified as pathogenic. -

Jun 24, 2022
Revvity Omics, Revvity
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 03, 2011
OMIM
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Sep 28, 2023
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:research

- -

not provided Pathogenic:3
Mar 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

CYP24A1: PM3:Very Strong, PM2:Supporting, PS3:Supporting -

Dec 23, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces leucine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 409 of the CYP24A1 protein (p.Leu409Ser). This variant is present in population databases (rs6068812, gnomAD 0.1%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with hypercalcemia and/or nephrolithiasis (PMID: 21675912, 23470222, 26214117, 26846157). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 29680). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt CYP24A1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects CYP24A1 function (PMID: 21675912, 23423976). For these reasons, this variant has been classified as Pathogenic. -

Oct 14, 2016
Molecular Diagnostics Lab, Nemours Children's Health, Delaware
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

CYP24A1-related disorder Pathogenic:1
Sep 19, 2024
PreventionGenetics, part of Exact Sciences
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

The CYP24A1 c.1226T>C variant is predicted to result in the amino acid substitution p.Leu409Ser. This variant has been reported as causative in the homozygous and compound heterozygous states in many individuals with autosomal recessive hypercalcaemia (Schlingmann et al. 2011. PubMed ID: 21675912; Mugg et al. 2015. PubMed ID: 25375986; Gahl WA et al 2016. PubMed ID: 26846157; Hanna C et al 2021. PubMed ID: 34307984). Functional studies indicate this variant has only ~32% of wild-type activity (Jacobs ET et al 2013. PubMed ID: 23423976; Mugg et al. 2015. PubMed ID: 25375986). This variant is reported in 0.13% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.90
BayesDel_addAF
Uncertain
0.052
T
BayesDel_noAF
Pathogenic
0.30
CADD
Pathogenic
29
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.79
D;.;.
Eigen
Pathogenic
0.86
Eigen_PC
Pathogenic
0.80
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Uncertain
0.89
D;T;D
M_CAP
Uncertain
0.27
D
MetaRNN
Uncertain
0.47
T;T;T
MetaSVM
Uncertain
0.58
D
MutationAssessor
Uncertain
2.1
M;M;.
PhyloP100
8.6
PrimateAI
Uncertain
0.62
T
PROVEAN
Uncertain
-3.7
D;D;D
REVEL
Uncertain
0.52
Sift
Uncertain
0.0010
D;D;D
Sift4G
Uncertain
0.0020
D;D;D
Polyphen
1.0
D;.;.
Vest4
0.93
MVP
0.97
MPC
0.44
ClinPred
0.10
T
GERP RS
5.3
Varity_R
0.93
gMVP
0.96
Mutation Taster
=6/94
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
Splicevardb
2.0
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs6068812; hg19: chr20-52774635; API